JP2021511042A5 - - Google Patents
Info
- Publication number
- JP2021511042A5 JP2021511042A5 JP2020539274A JP2020539274A JP2021511042A5 JP 2021511042 A5 JP2021511042 A5 JP 2021511042A5 JP 2020539274 A JP2020539274 A JP 2020539274A JP 2020539274 A JP2020539274 A JP 2020539274A JP 2021511042 A5 JP2021511042 A5 JP 2021511042A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide according
- nucleotides
- length
- oligonucleotide
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862617692P | 2018-01-16 | 2018-01-16 | |
| US62/617,692 | 2018-01-16 | ||
| PCT/US2019/013672 WO2019143621A1 (en) | 2018-01-16 | 2019-01-15 | Compositions and methods for inhibiting aldh2 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021511042A JP2021511042A (ja) | 2021-05-06 |
| JP2021511042A5 true JP2021511042A5 (enExample) | 2022-01-20 |
Family
ID=67302455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539274A Pending JP2021511042A (ja) | 2018-01-16 | 2019-01-15 | Ａｌｄｈ２発現を阻害するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11661603B2 (enExample) |
| EP (1) | EP3710588A4 (enExample) |
| JP (1) | JP2021511042A (enExample) |
| KR (1) | KR20200109311A (enExample) |
| CN (1) | CN111601891A (enExample) |
| AU (1) | AU2019209324A1 (enExample) |
| CA (1) | CA3086409A1 (enExample) |
| IL (1) | IL275539A (enExample) |
| MX (1) | MX2020007582A (enExample) |
| WO (1) | WO2019143621A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3710588A4 (en) | 2018-01-16 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS TO INHIBIT ALDH2 EXPRESSION |
| AU2020252560A1 (en) * | 2019-04-04 | 2021-10-28 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| WO2020226960A1 (en) | 2019-05-03 | 2020-11-12 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| TW202233839A (zh) | 2020-11-13 | 2022-09-01 | 美商戴瑟納製藥股份有限公司 | 用於抑制ａｌｄｈ２表現之化學修飾 |
| CN113174438B (zh) * | 2021-06-01 | 2022-07-26 | 中国科学院城市环境研究所 | Aldh2基因多态性检测试剂盒及检测方法 |
| JP2025518507A (ja) * | 2022-05-13 | 2025-06-17 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｓｎｃａの発現を阻害するための組成物及び方法 |
| CN114891808B (zh) * | 2022-06-21 | 2023-10-27 | 珠海丽凡达生物技术有限公司 | 编码ALDH2多肽的mRNA分子、应用及mRNA药物 |
| WO2024000237A1 (zh) * | 2022-06-29 | 2024-01-04 | 河南省农业科学院植物营养与资源环境研究所 | Iaa-po1基因在诱导平菇原基形成和平菇生长发育抗逆中的应用 |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| CN121294438A (zh) * | 2022-12-19 | 2026-01-09 | 昂拓生物医药有限公司 | 高级rna靶向(arnatar) |
| CN119082043A (zh) * | 2024-10-10 | 2024-12-06 | 张家界学院 | Aldh2稳定表达的细胞系、构建方法及应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032788A1 (en) | 1997-07-03 | 2003-02-13 | Thomas Jefferson University | Methods of inhibiting alcohol consumption |
| ATE338139T1 (de) * | 1999-08-30 | 2006-09-15 | Wisconsin Alumni Res Found | Herstellung von 3-hydroxypropionsäure in rekombinanten organismen |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2005116265A2 (en) | 2004-05-26 | 2005-12-08 | Wyeth | Probe arrays for expression profiling of rat genes |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| WO2010033225A2 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2010039543A2 (en) | 2008-09-23 | 2010-04-08 | Traversa Therapeutics, Inc. | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| KR20110110776A (ko) | 2008-12-18 | 2011-10-07 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| KR20120005240A (ko) | 2010-07-08 | 2012-01-16 | 한양대학교 산학협력단 | 제2알데하이드 탈수소효소의 발현을 억제하는 인공 마이크로 ｒｎａ 및 이의 이용 |
| CA2850792A1 (en) * | 2011-10-05 | 2013-04-11 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing aldehyde dehydrogenase |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| EP3140651B1 (de) | 2014-05-09 | 2022-10-26 | Oncimmune Germany GmbH | Markersequenzen zur diagnose und stratifizierung von systemische sklerose patienten |
| CN107109405A (zh) | 2014-06-06 | 2017-08-29 | 索尔斯蒂斯生物有限公司 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
| EP3865576A1 (en) * | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| US10689647B2 (en) * | 2015-05-08 | 2020-06-23 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA |
| MX2019002075A (es) | 2016-08-23 | 2019-07-01 | Dicerna Pharmaceuticals Inc | Composiciones que comprenden oligonucleotidos modificados reversiblemente, y sus usos. |
| WO2018045317A1 (en) | 2016-09-02 | 2018-03-08 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
| IL269517B2 (en) | 2017-04-05 | 2025-01-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of a target gene in a cell, conjugates thereof, compositions containing them, and medical uses thereof |
| US11015198B2 (en) | 2017-04-05 | 2021-05-25 | Silence Therapeutics Gmbh | Products and compositions |
| HRP20231063T1 (hr) | 2017-10-13 | 2023-12-22 | Novo Nordisk Health Care Ag | Postupci i pripravci namijenjeni inhibiranju eksprimiranja ldha |
| WO2019092282A1 (en) | 2017-11-13 | 2019-05-16 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of aldh2 in a cell |
| CN119120476A (zh) | 2017-11-13 | 2024-12-13 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中lpa的表达的核酸 |
| EP3710588A4 (en) | 2018-01-16 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS TO INHIBIT ALDH2 EXPRESSION |
| AU2020252560A1 (en) | 2019-04-04 | 2021-10-28 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| TW202233839A (zh) | 2020-11-13 | 2022-09-01 | 美商戴瑟納製藥股份有限公司 | 用於抑制ａｌｄｈ２表現之化學修飾 |
-
2019
- 2019-01-15 EP EP19741676.1A patent/EP3710588A4/en not_active Withdrawn
- 2019-01-15 WO PCT/US2019/013672 patent/WO2019143621A1/en not_active Ceased
- 2019-01-15 JP JP2020539274A patent/JP2021511042A/ja active Pending
- 2019-01-15 KR KR1020207020150A patent/KR20200109311A/ko not_active Ceased
- 2019-01-15 MX MX2020007582A patent/MX2020007582A/es unknown
- 2019-01-15 CN CN201980008527.XA patent/CN111601891A/zh active Pending
- 2019-01-15 CA CA3086409A patent/CA3086409A1/en active Pending
- 2019-01-15 AU AU2019209324A patent/AU2019209324A1/en not_active Abandoned
- 2019-01-15 US US16/961,918 patent/US11661603B2/en active Active
-
2020
- 2020-06-21 IL IL275539A patent/IL275539A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521796A5 (enExample) | ||
| JP2023536974A5 (enExample) | ||
| JP2019214587A5 (enExample) | ||
| JP2020529197A5 (enExample) | ||
| JP2023103244A5 (enExample) | ||
| JP2021518125A5 (enExample) | ||
| JP2023538284A5 (enExample) | ||
| JP2021006029A5 (enExample) | ||
| JP2022553348A5 (enExample) | ||
| JP2023535444A5 (enExample) | ||
| JP2021520207A5 (enExample) | ||
| CN117701562A (zh) | 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法 | |
| JP2021533804A5 (enExample) | ||
| JP2009514877A5 (enExample) | ||
| JP2007529224A5 (enExample) | ||
| JP2024037737A (ja) | Ｈｓｄ１７ｂ１３発現のモジュレータ | |
| TW202526019A (zh) | 用於治療血管收縮素原相關病症之方法及組成物 | |
| CN108513588A (zh) | Kras表达的调节剂 | |
| JP2021517826A5 (enExample) | ||
| JP2022503850A (ja) | 産物及び組成物 | |
| JP2024516356A5 (enExample) | ||
| JP2024531728A5 (enExample) | ||
| JP2024538859A5 (enExample) | ||
| JP2024535850A5 (enExample) | ||
| JP2022550979A5 (enExample) |